Industry News
Pharmaceutical Industry News
With the settlement, Celltrion can…
With the settlement, Celltrion can launch its recently approved Eylea biosimilar Eydenzelt on Dec. 31, 2026, in the same indications that Eylea treats.
Healthcare and pharma companies…
Healthcare and pharma companies sometimes engage with Hispanic audiences enthusiastically—but also often neglect the growing demographic.
Axial Therapeutics has stepped…
Axial Therapeutics has stepped back into the spotlight, emerging after almost two years of silence with a new name, focus and financing.
Novo said Tuesday that it will…
Novo said Tuesday that it will host an extraordinary general meeting on Nov. 14 to elect new members to its board following an impasse in leadership discussions involving the Danish drugmaker’s chief shareholder, the Novo
The company publicly responded to…
The company publicly responded to a Citizen Petition that urges the FDA to add warnings about the use of the over-the-counter pain med during pregnancy.
After clearing Novo Nordisk’s…
After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular events (MACE), the FDA has followed suit with a MACE expansion for its semaglutide pill Rybelsus.
Private equity firm Curewell…
Private equity firm Curewell Capital is aiming to close the gap in U.S. API production with a majority investment in specialty CDMO Wilmington PharmaTech.
ACG, a supplier for solid dose…
ACG, a supplier for solid dose drug manufacturers, is pumping $200 million into what will be the India-based company’s first empty-capsule production facility in the U.S.
As Big Pharmas increasingly roll…
As Big Pharmas increasingly roll out platforms for direct-to-consumer drug sales, most offering steep discounts on popular medications, many patients are open to using the new services, a recent survey found.
Merck has just registered the 15th…
Merck has just registered the 15th global phase 3 trial for its TROP2 antibody-drug conjugate, sac-TMT, just as its Chinese partner Kelun-Biotech reported two sets of strong phase 3 results in patients with lung cancer
Though spending on pharmaceutical…
Though spending on pharmaceutical TV ads picked up last month following a summer slump, the third quarter’s overall total still paled in comparison to the preceding periods this year.
Early Monday, Roche announced that…
Early Monday, Roche announced that the FDA cleared its 12-year-old oncology drug Gazyva to treat adults with active lupus nephritis who are taking standard therapy. The move into lupus nephritis comes late into the life
The investment is part of the New…
The investment is part of the New Jersey company’s plan to spend more than $70 billion on manufacturing, R&D and capital projects in the U.S. starting this year.
Theravance Biopharma is stepping…
Theravance Biopharma is stepping up efforts to educate physicians about neurogenic orthostatic hypotension associated with multiple system atrophy, launching its “Power in the Periphery” campaign in the run-up to publication of phase 3 data in
Novartis has shared detailed data…
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.
After upstaging Keytruda as…
After upstaging Keytruda as monotherapy for the treatment of first-line non-small cell lung cancer in China, Akeso and Summit Therapeutics’ ivonescimab has shown it could delay tumor progression versus another PD-1 inhibitor as part of
More than two years after a…
More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival showing for its combo could prohibit a broader FDA approval in ovarian cancer.
Merck offered a closer look at…
Merck offered a closer look at Keytruda's overall survival benefits in a PD-L1-positive subgroup and its broader progression-free survival win at ESMO 2025.
The FDA has endorsed Amgen and…
The FDA has endorsed Amgen and AstraZeneca’s Tezspire as an add-on maintenance treatment for patients age 12 and older with chronic rhinosinusitis with nasal polyps. It is the second indication for Tezspire, which was originally
Fertility drugmaker EMD Serono,…
Fertility drugmaker EMD Serono, the U.S. arm of Merck KGaA, will offer its in vitro fertilization (IVF) treatments at a sharp discount on the government's DTC platform TrumpRx.